PRD12: DETERMINING THE CLINICAL RELEVANCE OF STATISTICALLY SIGNIFICANT IMPROVEMENTS IN QUALITY OF LIFE  by Schleusener, D et al.
Abstracts 181
morning. The Rhinoconjunctivitis Quality of Life Ques-
tionnaire (RQLQ) created by Juniper and Guyatt was
transformed on to a digital optical character reading data
collection form. Patients completed the questionnaire at
baseline, week 1, and week 3. Statistical significance was
determined by the paired samples t test, and clinical sig-
nificance was determined by a previously set standard of
a 0.5 point change in the RQLQ score. 
RESULTS: The mean RQLQ score at base line was 2.75
(N  25, SD  1.08). The mean RQLQ score at the end
of week 3 was 1.26 (N  25, SD  .86). The mean score
improvement on the RQLQ was 1.49 points (lower
RQLQ score means better QOL). The improvement in
quality of life was both statistically (t  5.21; df  24;
p  0.001) and clinically significant. 
CONCLUSION: Loratadine 10 mg once a day improves
the quality of an allergic rhinitis patient’s life when used
for at least 3 weeks.
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OBJECTIVE: The purpose of this research was to deter-
mine the clinical relevance of an observed statistical im-
provement. 
METHODS: A randomized controlled trial was per-
formed to compare once daily fexofenadine HCl (120 mg
and 180 mg combined, n  559) to placebo (n  286) in
patients with seasonal allergic rhinitis. The Rhinitis Qual-
ity of Life Questionnaire (RQLQ), assessing quality of life
in the areas of activities, sleep, miscellaneous symptoms,
practical problems, nasal symptoms, eye symptoms and
emotions, was administered at baseline and 1 and 2 weeks
post-treatment. Mean change from baseline differences be-
tween treatments, averaged over weeks 1 and 2, were ana-
lyzed as the most powerful test of treatment differences.
However, it has been shown that a within-patient change
of 0.5 on the 7-point scale of the RQLQ is the minimum
difference of clinical relevance (Juniper et al., 1996). This
within-patient change was used to interpret statistically
significant mean differences. 
RESULTS: Patients receiving fexofenadine HCl showed
statistically significant mean improvements in total rhini-
tis related quality of life over patients receiving placebo
(mean  SE  0.39  0.05, 0.60  0.03 for placebo
and fexofenadine HCl patients respectively; p  0.0002).
The proportion of fexofenadine HCl patients who
showed a minimal clinically significant improvement of
0.5 or greater was also higher than patients receiving pla-
cebo (p  0.38, 0.48 for placebo and fexofenadine HCl
patients respectively, p  0.0045). 
CONCLUSIONS: In this study, a statistically significant
improvement in total rhinitis-related quality of life for
patients receiving once daily (120 mg and 180 mg) fex-
ofenadine HCl was also clinically relevant.
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OBJECTIVE: The study purpose was to develop an in-
strument to assess patient comfort and satisfaction with
prescribed nasal sprays in the treatment of seasonal aller-
gic rhinitis. 
METHODS: Standard instrument development method-
ology was utilized. A list of pertinent items obtained
from the literature was formulated. Each Nasal Comfort
Index (NCI) draft was scrutinized by experts regarding
item appropriateness, wording and anchor labels. Five-
point Likert scales were utilized. The NCI was organized
into pre-defined categories. Questions were included to
establish perceived importance of each category in order
to develop weights for determining a total score. Percep-
tion of content was assessed by 19 subjects. Qualitative
and quantitative data were collected. Item combination/
reduction was conducted after pre-test of the instrument.
Correlations between domain and total scores were cal-
culated to determine the best of four potential methods
for calculating these scores. 
RESULTS: Literature review revealed no existing vali-
dated methods for assessing patient comfort, satisfaction
and preferences in the target population. The final selec-
tion of items was based on qualitative and quantitative
analysis. The resultant NCI contained 20 items which,
through factor analysis, resulted in four domains explain-
ing 82% of the variance. The most appropriate scoring
method was deemed to be weighted means. 
CONCLUSIONS: Quantitative analysis confirmed many
qualitative findings. A single total score, combining the
domain scores, was considered the most clinically rele-
vant method for differentiating the effects of nasal
sprays. Validation analysis will occur on data gathered
through NCI implementation in a clinical trial.
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